Navigation Links
Solutia Reports First Quarter 2009 Results
Date:5/6/2009

-- -- --- End of period $35 $71 $83 === === === SUPPLEMENTAL DISCLOSURE OF CASH FLOW INFORMATION: Cash payments for interest $19 $6 $43 Cash payments for income taxes $2 $1 $4

Notes to Editor: Saflex and CPFilms are registered trademarks of Solutia Inc. and/or its subsidiaries.

Important Information Regarding Outlook

There is no guarantee that Solutia will achieve its projected financial expectation for 2009 which is based on management estimates, currently available information and assumptions which management believes to be reasonable. Such forward-looking statements are inherently subject to significant economic, competitive and other uncertainties and contingencies, many of which are beyond the control of management. See "Forward-Looking Statements" below.

Forward Looking Statements

This press release may contain forward-looking statements, which can be identified by the use of words such as "believes," "expects," "may," "will," "intends," "plans," "estimates," "estimated," or "anticipates," or other comparable terminology, or by discussions of strategy, plans or intentions. These statements are based on management's current beliefs, expectations and assumptions about the industries in which Solutia operates. Forward-looking statements are not guarantees of future performance and are subject to significant risks and uncertainties that may cause actual results or achievements to be materially different from the future results or achievements expressed or implied by the forward-looking statements. These risks and uncertainties include, but are not limited to, those risks and uncerta
'/>"/>

SOURCE Solutia Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21

Related biology technology :

1. Solutia to Present at Deutsche Bank Small and Mid Cap Conference
2. EpiCept Reports Expansion of Clinical Development For Licensed Cancer Compound
3. QMed, Inc. Reports July Medicare SNP Enrollments
4. Phlo Affiliate Reports Expanded Coverage to Oregon Border
5. Healthcare Technologies Reports Loss for 2007 Second Quarter & Six Months Results
6. Dragon Pharmaceutical Reports Growth in Sales and Profits during Second Quarter of 2007
7. Carrington Reports Second Quarter 2007 Results
8. Avitar Reports Third Quarter Financial Results for Fiscal 2007
9. Response Genetics Reports Second Quarter 2007 Financial Results
10. Cadence Pharmaceuticals Reports Second Quarter 2007 Financial Results
11. Transgenomic, Inc. Reports Second Quarter 2007 Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/30/2015)... WARREN, N.J. , April 30, 2015  Roka ... company focused on providing advanced testing solutions for the ... financial results for the first quarter of 2015 on ... markets. Roka Bioscience will also host a ... 7, 2015 to discuss its first quarter financial results. ...
(Date:4/30/2015)... Nitto Avecia, a leading biotechnology manufacturer ... and production capability to serve biotechnology pharmaceutical clients. ... fulfillment continues to drive Nitto Avecia to enhance ... , In Fall 2014, Nitto Avecia ... at its Milford, MA facility, which is recognized ...
(Date:4/30/2015)... April 30, 2015  The Paul G. Allen Family ... (ADI) grants to six groups of researchers with projects ... roadblocks in neuroscience: growing mature human brain cells in ... of $7.5 million over three years.  ... research is especially significant because the field of neuronal ...
(Date:4/30/2015)... WuXi PharmaTech (Cayman) Inc. ("WuXi" or the "Company") (NYSE: ... provider, today announced that its board of directors has ... 2015, from a consortium (the "Consortium") led by Dr. ... chief executive officer of the Company, and Ally Bridge ... "Transaction") involving the acquisition of all outstanding shares of ...
Breaking Biology Technology:Roka Bioscience to Report First Quarter 2015 Financial Results On May 7, 2015 2Biotechnology Manufacturer Nitto Avecia Expands Capacity to Meet Client Demand 2The Paul G. Allen Family Foundation Awards $7.5 Million To Study Brain Cell Growth And Development 2The Paul G. Allen Family Foundation Awards $7.5 Million To Study Brain Cell Growth And Development 3The Paul G. Allen Family Foundation Awards $7.5 Million To Study Brain Cell Growth And Development 4The Paul G. Allen Family Foundation Awards $7.5 Million To Study Brain Cell Growth And Development 5WuXi PharmaTech Announces Receipt of Proposal 2WuXi PharmaTech Announces Receipt of Proposal 3WuXi PharmaTech Announces Receipt of Proposal 4WuXi PharmaTech Announces Receipt of Proposal 5WuXi PharmaTech Announces Receipt of Proposal 6
... INDIANAPOLIS, Oct. 30, 2009 Amylin Pharmaceuticals, Inc., (Nasdaq: ... ) today announced that the U.S. Food and Drug Administration ... BYETTA is now approved for use as a stand-alone medication ... in adults with type 2 diabetes. Previously, it was approved ...
... Calif., Oct. 30 ThermoGenesis Corp. (Nasdaq: ... and store adult stem cells, announced today it will report ... 2009, on Thursday, November 5, 2009. , ... host a conference call Thursday, November 5, 2009 at 2:00 ...
... , ROCKVILLE, Md., Oct 30 Novavax, Inc. (Nasdaq: ... third quarter financial results in a press release to be ... 2009. The Company will hold an investor conference call to ... Friday, November 6, 2009. The call will be hosted by ...
Cached Biology Technology:BYETTA Approved for Expanded Use as First-Line Treatment for Type 2 Diabetes 2BYETTA Approved for Expanded Use as First-Line Treatment for Type 2 Diabetes 3BYETTA Approved for Expanded Use as First-Line Treatment for Type 2 Diabetes 4BYETTA Approved for Expanded Use as First-Line Treatment for Type 2 Diabetes 5BYETTA Approved for Expanded Use as First-Line Treatment for Type 2 Diabetes 6BYETTA Approved for Expanded Use as First-Line Treatment for Type 2 Diabetes 7Thermogenesis Corp. to Announce First Quarter Fiscal 2010 Results on November 5, 2009 2Novavax Announces Release Date of 2009 Third Quarter Financial Results and Investor Conference Call 2
(Date:4/10/2015)... April 10, 2015 Research and ... the "Security Competitive Profiles - NEC" report ... NEC will continue to supply a range ... market, with a company focus on the development of ... Winning opportunities in the Asia-Pacific ...
(Date:4/8/2015)... April 8, 2015  Infinisource, a leading provider ... and Morpho, a leading supplier of biometric identification ... the market,s most advanced biometrically-enabled time clock, the ... time clock is setting a bold, new standard ... for the small and mid-size employer. When connected ...
(Date:4/2/2015)... HAMBURG, Germany , April 2, 2015 /PRNewswire/ ... ten fingerprint tests DERMALOG by far outperforms the ... While always maintaining high accuracy, the system is ... second. Hence, the speed proves up to be ... 40% faster than its runner-up performance. ...
Breaking Biology News(10 mins):NEC Security Competitive Profile 2015 2iSolved Time Clock Offers Unmatched Accuracy due to Morpho Biometrics 2iSolved Time Clock Offers Unmatched Accuracy due to Morpho Biometrics 3DERMALOG AFIS Emerges as Performance Winner in NIST Benchmark Test 2DERMALOG AFIS Emerges as Performance Winner in NIST Benchmark Test 3
... The first real-world, demonstration-scale project in Nevada for ... stage of research at the University of Nevada, Reno. ... is an economical, commercially viable renewable energy source in ... outdoor cold-weather crop of algae as part of their ...
... TGen Clinical Research Services (TCRS) at Scottsdale Healthcare ... may offer broad potential to treat solid tumors. ... conducted at TGen Clinical Research Services at Scottsdale Healthcare, ... (TGen) and Scottsdale-based Scottsdale Healthcare Corp., and at Mayo ...
... bleaching is not only a con, but is dangerous to ... journal. The light treatment gives absolutely no benefit over ... four times as much as sunbathing, reports a study in ... match Tom Cruise,s glittering pearly-whites would be better off ignoring ...
Cached Biology News:Success for first outdoor, large-scale algae-to-biofuel research project in Nevada 2TGen Clinical Research Services at Scottsdale Healthcare and Mayo Clinic study new cancer drug 2
... Continuing a tradition of progressive centrifuge design ... series. The Centra-CL3 and Centra-CL3R (refrigerated) general ... laboratory., Quality Control Over Sample Preparation ... lock up to 99 protocols and has ...
... Molecular Probes intensely fluorescent and ... potential for use in a variety ... deliver a strong signal. Unfortunately, protein- ... regions that may cause them to ...
... Centra-CL5R multi-purpose centrifuge offers both high-speed ... assortment of rotor options, making it ... applications., Maximum Versatility , High-speed ... angle rotors or high-volume (4 x 250mL) ...
... licensed, high throughput, water bath thermal cycler capable ... microplates. This equates to 9,216 reactions per run ... rapidly transfers a basket of plates between three ... are considerably faster than those of peltier block ...
Biology Products: